<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e>-reperfusion injury is a common complication of <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> that is the leading cause of <z:hpo ids='HP_0011420'>death</z:hpo> worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we plan to elucidate <z:chebi fb="5" ids="7872">oxytocin</z:chebi> cardioprotection effects against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion via nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO), reactive oxygen species (ROS), and protein kinase C (PKC) in anesthetized rat preconditioned myocardium </plain></SENT>
<SENT sid="2" pm="."><plain>Forty-eight Sprague-Dawley rats were equally divided into eight groups </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> animals were subjected to 25 min <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and 120 min reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="5" ids="7872">Oxytocin</z:chebi> (OT), L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (<z:chebi fb="17" ids="48010">LNA</z:chebi>, a nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase inhibitor), chelerythrine (CHE, a PKC <z:chebi fb="0" ids="23924">enzyme inhibitor</z:chebi>), and <z:chebi fb="0" ids="28939">N-acetylcysteine</z:chebi> (NAC, a ROS scavenger) were used prior to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Results showed that mean arterial pressure significantly reduced during the first 10 min of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and reperfusion in IR, <z:chebi fb="17" ids="48010">LNA</z:chebi>, CHE, and NAC groups (p&lt;0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>OT prevented mean arterial pressure decline during early phase of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain>Cardioprotective effects of OT in <z:mpath ids='MPATH_124'>infarct</z:mpath> size, plasma levels of <z:chebi fb="2" ids="16919">creatine</z:chebi> kinase-MB and <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase, severity and incidence of <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> were abolished by L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>, chelerythrine, and <z:chebi fb="0" ids="28939">N-acetylcysteine</z:chebi> (p&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>The present study showed that OT pretreatment reduces myocardial <z:mpath ids='MPATH_124'>infarct</z:mpath> size and <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, and improves mean arterial pressure via NO production, PKC activation, and ROS balance </plain></SENT>
<SENT sid="9" pm="."><plain>These findings provide new insight into therapeutic strategies for <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> </plain></SENT>
</text></document>